Compare SKYE & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYE | REFI |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 222.4M |
| IPO Year | 2013 | 2021 |
| Metric | SKYE | REFI |
|---|---|---|
| Price | $1.06 | $8.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $9.00 | ★ $14.83 |
| AVG Volume (30 Days) | 102.2K | ★ 131.6K |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | ★ 21.78% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $48,857,628.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.34 |
| P/E Ratio | ★ N/A | $10.55 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $8.48 |
| 52 Week High | $11.04 | $13.49 |
| Indicator | SKYE | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 35.72 |
| Support Level | $0.50 | N/A |
| Resistance Level | $1.66 | $9.43 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 56.66 | 0.00 |
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.